Your browser doesn't support javascript.
loading
N-Adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as Fluorescent Probes to Detect Microglia Activation through the Imaging of Cannabinoid Receptor Subtype 2 (CB2R).
Intranuovo, Francesca; Majellaro, Maria; Mastropasqua, Francesco; Delre, Pietro; Abatematteo, Francesca Serena; Mangiatordi, Giuseppe Felice; Stefanachi, Angela; Brea, Josè; Loza, Maria Isabel; Riganti, Chiara; Ligresti, Alessia; Kumar, Poulami; Esposito, Daniela; Cristino, Luigia; Nicois, Alessandro; González, Lucía; Perrone, Maria Grazia; Colabufo, Nicola Antonio; Sotelo, Eddy; Abate, Carmen; Contino, Marialessandra.
Afiliación
  • Intranuovo F; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy.
  • Majellaro M; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15782 Santiago, Spain.
  • Mastropasqua F; Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Delre P; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy.
  • Abatematteo FS; Institute of Crystallography, National Research Council of Italy, Via Amendola, 122/o, 70126 Bari, Italy.
  • Mangiatordi GF; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy.
  • Stefanachi A; Institute of Crystallography, National Research Council of Italy, Via Amendola, 122/o, 70126 Bari, Italy.
  • Brea J; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy.
  • Loza MI; Innopharma Screening Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Riganti C; Department of Pharmacology, Pharmacy and Pharmaceutical Technology. School of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Ligresti A; Innopharma Screening Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Kumar P; Department of Pharmacology, Pharmacy and Pharmaceutical Technology. School of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Esposito D; Dipartimento di Oncologia, Università degli Studi di Torino, 10124 Torino, Italy.
  • Cristino L; National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli (NA), Italy.
  • Nicois A; National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli (NA), Italy.
  • González L; National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli (NA), Italy.
  • Perrone MG; National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli (NA), Italy.
  • Colabufo NA; National Research Council of Italy, Institute of Biomolecular Chemistry, 80078 Pozzuoli (NA), Italy.
  • Sotelo E; Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15782 Santiago, Spain.
  • Abate C; Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Contino M; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy.
J Med Chem ; 67(13): 11003-11023, 2024 Jul 11.
Article en En | MEDLINE | ID: mdl-38937147
ABSTRACT
Cannabinoid receptor subtype 2 (CB2R) is emerging as a pivotal biomarker to identify the first steps of inflammation-based diseases such as cancer and neurodegeneration. There is an urgent need to find specific probes that may result in green and safe alternatives to the commonly used radiative technologies, to deepen the knowledge of the CB2R pathways impacting the onset of the above-mentioned pathologies. Therefore, based on one of the CB2R pharmacophores, we developed a class of fluorescent N-adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives spanning from the green to the near-infrared (NIR) regions of the light spectrum. Among the synthesized fluorescent ligands, the green-emitting compound 55 exhibited a favorable binding profile (strong CB2R affinity and high selectivity). Notably, this ligand demonstrated versatility as its use was validated in different experimental settings such as flow cytometry saturation, competitive fluorescence assays, and in vitro microglia cells mimicking inflammation states where CB2R are overexpressed.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Microglía / Receptor Cannabinoide CB2 / Colorantes Fluorescentes Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Asunto principal: Microglía / Receptor Cannabinoide CB2 / Colorantes Fluorescentes Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: Italia